Dr. Dan Hanley

A leading expert on brain injury, Dr. Daniel F. Hanley has been a professor of neurology, neurosurgery, and anesthesiology/critical care medicine at the Johns Hopkins University School of Medicine since 1996 and was named the Jeffrey and Harriet Legum Chair of Acute Care Neurology. Dr. Hanley founded and directed the Johns Hopkins Neurocritical Care Unit, one of the first critical care units dedicated solely to neurosurgical and neurological patients. Subsequently, in 1999, he founded and continues to direct the BIOS Clinical Trials Coordinating Center (BIOS CTCC), formerly known as the Division of Brain Injury Outcomes. Under Dr. Hanley’s leadership, BIOS CTCC, an academic contract research organization based at Johns Hopkins, has organized and completed more than 20 large clinical trials. He has been awarded over 70 clinical and basic research grants, predominantly from the National Institutes of Health and the FDA Orphan Products Grants Program. Dr. Hanley’s 40-year career in medicine has focused on clinical trial design, the organization and interpretation of drug and device trials, the development of strategic research plans, and FDA regulatory compliance. He has led international, NIH-sponsored trials including the MISTIE III and CLEAR III trials investigating minimally invasive neurosurgical techniques to treat hemorrhagic stroke. As principal investigator for the National Center for Advancing Translational Sciences (NCATS) Johns Hopkins Trial Innovation Center, Dr. Hanley leads collaborative efforts to advance education and therapeutics through innovative CTSA clinical trials. Currently, Dr. Hanley is the PI or multi-PI for several ongoing trials. These include a multisite phase 2/3 randomized controlled dementia prevention trial (MAP), a large multicenter clinical trial involving automated monitoring of atrial fibrillation (REACT AF), and a first-in-patient phase 2a biomarker and edema attenuation in intracerebral hemorrhage trial (BEACH). Dr. Hanley has published over 400 peer-reviewed articles and book chapters, received the Humboldt Research Prize for accomplishments in brain injury research, and mentored nearly 100 researchers. His trainees, which include a large number of trialists, have led 25 brain intensive care units, and over 40 have been named full professors, program leaders, or department chairs. He has served on public boards including the American Academy of Neurology, National Stroke Association, and NIH National Institute of Nursing Research.

Dr. Hanley is rated as an Elite provider by MediFind in the treatment of Stroke. His top areas of expertise are Stroke, Hydrocephalus, Vertigo, Severe Acute Respiratory Syndrome (SARS), and Thrombectomy.

His clinical research consists of co-authoring 291 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 60 articles in the study of Stroke.